HomeMarket News European Medicines Agency Investigates GLP-1s and Suicidal Thoughts Amidst...

European Medicines Agency Investigates GLP-1s and Suicidal Thoughts Amidst Growing Concerns

Actionable Trade Ideas

always free

Insulin injection pen or insulin cartridge pen for diabetics.

CR

European regulators are intensifying their focus on the possible link between certain diabetes and weight-loss drugs, known as GLP-1s, and suicidal thoughts. The European Medicines Agency (EMA) has launched an investigation in response to numerous reports of adverse events possibly associated with these medications, involving key players in the industry such as Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).

The EMA initiated the review in July following the receipt of over 170 reports detailing suspected adverse events related to the drugs in question. This week, the EMAโ€™s Pharmacovigilance Risk Assessment Committee convened to deliberate the matter and plans to reconvene on the issue in April, as per a report from Reuters.

According to Reuters, the EMA has emphasized, โ€œWhile at this point no conclusion can be drawn on causal association, there are several issues that still need to be clarified.โ€

Notably, the review is centered on GLP-1 receptor agonists, a category of medications encompassing Novo Nordiskโ€™s Rybelsus, Saxenda, Wegovy, and Ozempic; Lillyโ€™s Trulicity; AstraZenecaโ€™s (NASDAQ:AZN) Bydureon and Byetta; as well as Sanofiโ€™s (NASDAQ:SNY) Suliqua. However, it excludes Lillyโ€™s Mounjaro and Zepound, which belong to a different molecular class.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.